Natural Capsules working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
92.34×92.34×109.44×
130.24×130.24×134.26×
167.31×167.31×165.54×
55.27×55.27×78.16×
46.86×45.99×5.72×
0.44×0.44×0.40×
−0.44×−0.44×43.33×
−7.00×−7.00×1.53×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCAPSUQ₹137.93

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLABMcap ₹143 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)109.4492.3492.34
Receivable Days (DSO)134.26130.24130.24
Payable Days (DPO)165.54167.31167.31
Cash Conversion Cycle (days)78.1655.2755.27
Working Capital Turnover5.7245.9946.86
Asset Turnover0.400.440.44
Cash Conversion (CFO/Net Income)43.33-0.44-0.44
CFO/EBITDA1.53-7.00-7.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.